APLS
Apellis Pharmaceuticals, Inc.
61.58
USD
This page is just a preview of the data found in TrendSpider’s full version
Apellis Pharmaceuticals, Inc. stock is up 31.5% since 30 days ago. The next earnings date is Feb 20, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 85.71% of the previous 6 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 01 Dec 18:18 | 19 Jan, 2024 | 50.00 | 861 | ||
| 01 Dec 18:20 | 19 Jan, 2024 | 60.00 | 5689 | ||
| 01 Dec 18:22 | 19 Jan, 2024 | 50.00 | 861 | ||
| 01 Dec 18:51 | 15 Dec, 2023 | 60.00 | 4148 | ||
| 01 Dec 19:08 | 19 Jan, 2024 | 60.00 | 5689 | ||
| 01 Dec 20:06 | 19 Jan, 2024 | 70.00 | 540 | ||
| 01 Dec 20:18 | 15 Dec, 2023 | 60.00 | 4148 | ||
| 01 Dec 20:19 | 15 Dec, 2023 | 60.00 | 4148 | ||
| 01 Dec 20:37 | 19 Jan, 2024 | 55.00 | 457 | ||
| 01 Dec 20:40 | 19 Jan, 2024 | 60.00 | 5689 |
Apellis Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.
